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Abstract
Unraveling the mechanisms underlying the
inflammatory response in rheumatoid arthritis is crucial
in order to better understand the disease and to
develop novel therapeutic approaches. Although the
effect of type I interferons on fibroblasts and in the
context of rheumatoid arthritis has been described for
some time, little is known on the effects of the type III
interferons, also known as IFNλ. In a previous issue, Xu
and colleagues demonstrate that one of the members
of the IFNλ family, IFNλ1, enhances Toll-like receptor
expression and consequently promotes the production
of proinflammatory cytokines known to be involved in
initiating and maintaining the inflammatory responses
in rheumatoid arthritis.
Interferons, known for their anti-viral, anti-proliferative,
and immunomodulatory effects, are one of the immune
system’s first lines of defense against bacterial and viral
infections. Three classes of interferons have been de-
scribed, designated type I, type II, and type III, and are
distinguished by the unique complimentary receptor
complexes through which they signal (Figure 1). Type I
interferons, which are comprised of 13 IFNα subtypes as
well as IFNβ, IFNω, and various others, engage through
the IFNα receptor complex, composed of IFNαR1 and
IFNαR2 chains. Type I interferons have been well de-
scribed and are used as a therapeutic for a myriad of dis-
eases, including viral infections, autoimmune diseases,
and even various forms of cancer. More recently, type
III interferons, also known as the IFNλ family, have be-
come of particular interest in the immunological field,
with recent publications focusing on rheumatoid arth-
ritis (RA) [1,2]. The IFNλ family, comprised of IFNλ1,
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IFNλ2, IFNλ3, and IFNλ4, engage through the IL-28RA
and IL-10R2 complex. Despite triggering distinct recep-
tor complexes, the downstream signaling of both type I
and type III interferons is regulated through Janus kin-
ase/signal transducers and activators of transcription sig-
nal transduction, ultimately resulting in the induction of
interferon-stimulated response elements and initiation of
gene transcription. Opposed to the IFNα receptor, which
is ubiquitously expressed, the IFNλ receptor is more lim-
itedly expressed, potentially making it a more specific
activator of immune responses.
When first described, IFNλ was suggested to primarily
act on cells of epithelial origin [3], making it an activator
of the innate immune response. Hepatocytes, also shown
to be responsive to IFNλ stimulation [4], only became of
particular interest after the discovery of single nucleotide
polymorphisms located near the gene encoding for
IFNλ3 that were associated with spontaneous as well as
therapy-induced clearance of the hepatitis C virus [5],
but also demonstrating that activity of IFNλ was not
restricted to epithelial cells.
The article by Xu and colleagues in a previous issue of
Arthritis Research & Therapy describes the effects of
IFNλ on fibroblasts and its context in RA [1]. Previously,
the same research group demonstrated that IFNλ1 was
expressed at higher levels in peripheral blood mono-
nuclear cells, serum, synovial fluid, and synovium in RA
patients as compared with healthy individuals [2]. They
now continue by showing that IFNλ1 is able to enhance
Toll-like receptor expression and consequently Toll-like
receptor-induced IL-6 and IL-8 production in the RA
synovial fibroblasts, contributing to RA synovial inflam-
mation. Importantly, these effects are not only described
in cell fibroblast cell lines, but also in primary fibroblasts
IFNλ and its modulation of Toll-like receptor activation
has also been described in monocyte-derived macro-
phages, where IFNλ incubation resulted in enhanced IL-
12p40 and tumor necrosis factor production [6]. Aside
from macrophages, B cells [7], and plasmacytoid den-
dritic cells [8], limited literature has described IFNλ and
its effects on immune cells. Monocytes and natural killer
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cells, first reported to be IFNλ-responsive cellular sub-
sets, have since been described as unresponsive [6,9].
Due to an initial focus on anti-viral activity, the im-
munological role and activity of IFNλ on immune cell
populations still remain incomplete. However, increasing
evidence suggests that IFNλ also plays a larger role in
immunoregulation.
Xu and colleagues convincingly show that IFNλ may
have a detrimental effect for RA patients by enhancing
fibroblast-mediated proinflammatory cytokines, which
may ultimately contribute to synovial inflammation.
Similar effects have been described for IFNα in RA syn-
ovial fibroblasts [10], and a large portion of the litera-
ture has focused on the similarities between type I and
type III interferons. The distinctions between these two
classes of cytokines, however, remain almost com-
pletely undefined. Only differences between type I and
type III interferons have thus far been reported in the
regulation of proinflammatory cytokine production by
macrophages [6], making it imperative to further inves-
tigate the unique qualities of IFNλ. The introduction of
fibroblasts as an IFNλ-responsive population is an im-
portant finding, and may stimulate research into the
underlying causes of inflammation in RA. Synovial
macrophages, another central population in RA re-
search, have yet to be investigated for their response to
IFNλ. This, in combination with the data presented by
Xu and colleagues on RA synovial fibroblasts, could
provide a more complete understanding of the im-
munological role of IFNλ in RA.
Abbreviations
IFN: Interferon; IL: Interleukin; RA: Rheumatoid arthritis.
Competing interests
AB has received a research grant from Bristol-Myers-Squibb to investigate
the biological effects of IL-29.
Acknowledgements
The studies by the authors were supported by the Virgo consortium, funded
by the Dutch government (project number FES0908) and by the Netherlands
Genomics Initiative (project number 050-060-452).
Author details
1Department of Gastroenterology and Hepatology, Erasmus MC, University
Medical Center Rotterdam, ‘s-Gravendijkwal 230, Room Na-1011, 3015 CE,
Rotterdam, the Netherlands. 2Department of Rheumatology, Leiden
University Medical Center, PO Box 9600 2300 RC, Leiden, the Netherlands.
Published:
References
1. Xu LF, Feng X, Tan W, Gu W, Guo D, Zhang M, Wang F: IL-29 enhances Toll-like
receptor-mediated IL-6 and IL-8 production by the synovial fibroblasts from
rheumatoid arthritis patients. Arthritis Res Ther 2013, 15:R170.
2. Wang F, Xu L, Feng X, Guo D, Tan W, Zhang M: Interleukin-29 modulates
proinflammatory cytokine production in synovial inflammation of
rheumatoid arthritis. Arthritis Res Ther 2012, 14:R228.
3. Sommereyns C, Paul S, Staeheli P, Michiels T: IFN-lambda (IFN-λ) is
expressed in a tissue-dependent fashion and primarily acts on epithelial
cells in vivo. PLoS Pathog 2008, 4:e1000017.
4. Doyle SE, Schreckhise H, Khuu-Duong K, Henderson K, Rosler R, Storey H,
Yao L, Liu H, Barahmand-pour F, Sivakumar P, Chan C, Birks C, Foster D,
Clegg CH, Wietzke-Braun P, Mihm S, Klucher KM: Interleukin-29 uses a type
1 interferon-like program to promote antiviral responses in human hepa-
tocytes. Hepatology 2006, 44:896–906.
5. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, Heinzen EL,
Qiu P, Bertelsen AH, Muir AJ, Sulkowski M, McHutchison JG, Goldstein DB:
Figure 1 Interferon classes are distinguished by the unique complimentary receptor complexes through which they signal. IFNα, and
other type 1 interferons (IFNs), engage through the IFNα receptor complex, composed of IFNαR1 and IFNαR2, while IFNλ signals through the IL-
28RA and IL-10R2 complex. Despite triggering distinct receptor complexes, the downstream signaling of both IFNα and IFNλ is regulated through
JAK/STAT signal transduction, ultimately resulting in the induction of IFN-stimulated response elements (ISRE) and initiation of gene transcription.
Opposed to the ubiquitously expressed IFNα receptor, the IFNλ receptor appears to be more limited in its expression. IRF, interferon regulatory
factor; ISGF, interferon-stimulated gene factor; JAK, Janus kinase; STAT, signal transducers and activators of transcription; TYK, tyrosine.
de Groen et al. Arthritis Research & Therapy Page 2 of 3
21 Jan 2014
2014, 16:102
http://arthritis-research.com/content/16/1/102
Genetic variation in IL28B predicts hepatitis C treatment-induced viral
clearance. Nature 2009, 461:399–401.
6. Liu BS, Janssen HL, Boonstra A: IL-29 and IFNα differ in their ability to
modulate IL-12 production by TLR-activated human macrophages and
exhibit differential regulation of the IFNgamma receptor expression.
Blood 2011, 117:2385–2395.
7. Novak AJ, Grote DM, Ziesmer SC, Rajkumar V, Doyle SE, Ansell SM: A role for
IFN-λ1 in multiple myeloma B cell growth. Leukemia 2008, 22:2240–2246.
8. Megjugorac NJ, Gallagher GE, Gallagher G: Modulation of human plasmacytoid
DC function by IFN-λ1 (IL-29). J Leukoc Biol 2009, 86:1359–1363.
9. Kramer B, Eisenhardt M, Glassner A, Korner C, Sauerbruch T, Spengler U,
Nattermann J: Do lambda-IFNs IL28A and IL28B act on human natural
killer cells? Proc Natl Acad Sci U S A 2011, 108:E519–E520. author reply
E521-E522.
10. Roelofs MF, Wenink MH, Brentano F, Abdollahi-Roodsaz S, Oppers-Walgreen
B, Barrera P, van Riel PL, Joosten LA, Kyburz D, van den Berg WB, Radstake
TR: Type I interferons might form the link between Toll-like receptor
(TLR) 3/7 and TLR4-mediated synovial inflammation in rheumatoid
arthritis (RA). Ann Rheum Dis 2009, 68:1486–1493.
Cite this article as: de Groen et al.: Understanding IFNλ in rheumatoid
arthritis. Arthritis Research & Therapy
de Groen et al. Arthritis Research & Therapy Page 3 of 3
10.1186/ar4445
2014, 16:102
2014, 16:102
http://arthritis-research.com/content/16/1/102
